# US 2026/0108570 A1 · Bacteriophage compositions and methods for treatment of bacterial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0108570 A1
- Document ID: US20260108570A1
- Status: Published application
- Kind: A1
- Application number: 19/100,379
- Filed: 2023-08-01
- Published: 2026-04-23
- Earliest claimed: 2022-08-01
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Mark MIMEE; Ella ROTMAN
- Web page: https://patentgrep.com/patent/US20260108570A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/02: Recovery or purification
- A61P 31/04: Antibacterial agents
- C12N 2795/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more isolated bacteriophage comprising a bacterio-phage sequence that is at least 99% identical to any one of SEQ ID NO:1-74. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic Klebsiella infection.

## Claims

### Claim at position 1

1-153. (canceled)

### Claim 154

A composition comprising a collection of isolated bacteriophage comprising:
i. an Ackermannviridae bacteriophage, a Tevenvirinae bacteriophage, a Slopekvirus bacteriophage, a Siphoviridae bacteriophage, and/or a Demerecviridae bacteriophage;
ii. an Autographiviridae bacteriophage, a Tevenvirinae bacteriophage, one or more Slopekvirus bacteriophage, and/or a Purpuraviridae bacteriophage; or
iii. an Autographiviridae bacteriophage, a Tevenvirinae bacteriophage, one or more Slopekvirus bacteriophage, a Demerecviridae bacteriophage, and/or a Purpuraviridae bacteriophage.

### Claim 155 (depends on 154)

The composition of claim 154, wherein:
for the collection of isolated bacteriophage of (i):
the Ackermannviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:1 or SEQ ID NO:37;
the Tevenvirinae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:2 or SEQ ID NO:40;
the Slopekvirus bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:3 or SEQ ID NO:41;
the Siphoviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:4 or SEQ ID NO:52; and
the Demerecviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:5 or SEQ ID NO:56;
for the collection of isolated bacteriophage of (ii):
the Autographiviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:74;
the Tevenvirinae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:14 or SEQ ID NO:36;
the one or more Slopekvirus bacteriophage comprise two Slopekvirus bacteriophage, and the Slopekvirus are isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:20 or SEQ ID NO:47 and SEQ ID NO:22 or SEQ ID NO:49; and
the Purpuraviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:8 or SEQ ID NO:32; and
for the collection of isolated bacteriophage of (iii):
the Autographiviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:25 or SEQ ID NO:53;
the Tevenvirinae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:2 or SEQ ID NO:40;
the Slopekvirus bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:20 or SEQ ID NO:47;
the Demerecviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:5 or SEQ ID NO:46; and
the Purpuraviridae bacteriophage is an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to SEQ ID NO:72.

### Claim 156 (depends on 154)

The composition of claim 154, wherein:
for the collection of isolated bacteriophage of (i):
the Ackermannviridae bacteriophage is ΦER12;
the Tevenvirinae bacteriophage is ΦER15;
the Slopekvirus bacteriophage is ΦER16;
the Siphoviridae bacteriophage is ΦER39; and
the Demerecviridae bacteriophage is ΦER46;
for the collection of isolated bacteriophage of (ii):
the Autographiviridae bacteriophage is ΦMM9;
the Tevenvirinae bacteriophage is ΦER11;
the one or more Slopekvirus bacteriophage comprise two Slopekvirus, and the two Slopekvirus are ΦER27 and ΦER36; and
the Purpuraviridae bacteriophage is ΦER3; and
for the collection of isolated bacteriophage of (iii):
the Autographiviridae bacteriophage is ΦER43;
the Tevenvirinae bacteriophage is ΦER15;
the Slopekvirus bacteriophage is ΦER27;
the Demerecviridae bacteriophage is ΦER46; and
the Purpuraviridae bacteriophage is ΦMM7.

### Claim 157

A composition comprising at least one isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to any one of SEQ ID NO:1-74.

### Claim 158 (depends on 157)

The composition of claim 157, wherein the composition comprises no more than one, two, three, four, or five isolated bacteriophage.

### Claim 159 (depends on 157)

The composition of claim 157, wherein the one, two, three, four, or five different isolated bacteriophage each comprises a bacteriophage sequence that is at least 99.1, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical to any one of SEQ ID NO: 1-74.

### Claim 160 (depends on 157)

The composition of claim 157, wherein the one, two, three, four, or five different isolated bacteriophage each comprises a bacteriophage sequence that is at least 99.1, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 99.95% identical to or comprises any one of:
SEQ ID NO:1 or SEQ ID NO:37; SEQ ID NO:2 or SEQ ID NO:40; SEQ ID NO:3 or SEQ ID NO: 41; SEQ ID NO:4 or SEQ ID NO:52; or SEQ ID NO:5 or SEQ ID NO:56;
SEQ ID NO:8 or SEQ ID NO:32, SEQ ID NO: 14 or SEQ ID NO:36, SEQ ID NO:20 or SEQ ID NO:47, SEQ ID NO:22 or SEQ ID NO:49, or SEQ ID NO: 74; or
SEQ ID NO:2 or SEQ ID NO:40; SEQ ID NO:20 or SEQ ID NO:47; SEQ ID NO:25 or SEQ ID NO:53; SEQ ID NO:5 or SEQ ID NO:56; or SEQ ID NO:72.

### Claim 161 (depends on 157)

The composition of claim 157, wherein the one, two, three, four, or five different isolated bacteriophage each comprises a bacteriophage sequence with no more than 20 nucleotide changes in any one of SEQ ID NO: 1-74.

### Claim 162 (depends on 157)

The composition of claim 157, wherein the isolated bacteriophage further comprises a heterologous sequence comprising a peptide or polypeptide.

### Claim 163 (depends on 157)

The composition of claim 157, wherein the composition comprises about 108 to about 1012 plaque forming units (PFU) per milliliter (PFU/ml) of isolated bacteriophages.

### Claim 164 (depends on 157)

The composition of claim 157, further comprising a pharmaceutically acceptable carrier or an antibiotic drug.

### Claim 165 (depends on 157)

A method of increasing the susceptibly of a drug-resistant and/or pathogenic Klebsiella strain in a subject to clearance by the subject's immune system or to conventional antibiotic treatment, the method comprising the step of administering to the subject a therapeutically effective amount of the composition of claim 157.

### Claim 166 (depends on 157)

A method of reducing the level or virulence of a drug-resistant and/or pathogenic Klebsiella strain or reducing the number of capsulated Klebsiella in a subject in a subject, comprising the step of administering to the subject a therapeutically effective amount of the composition of claim 157.

### Claim 167

A method for treating and/or preventing a Klebsiella infection in a subject comprising administering to the subject a composition comprising at least one isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to any one of SEQ ID NO: 1-74.

### Claim 168 (depends on 167)

The method of claim 167, wherein the Klebsiella is drug-resistant, hypervirulent, and/or from Klebsiella pneumoniae, Klebsiella quasipneumoniae, and/or Klebsiella variicola.

### Claim 169 (depends on 167)

The method of claim 167, wherein the subject has symptoms of a Klebsiella infection, is at risk for a Klebsiella infection, or has been determined to be infected with Klebsiella.

### Claim 170 (depends on 167)

The method of claim 167, wherein the infection is an infection of the urinary tract, blood, gut, abdomen, stomach, lungs, skin, ear, eye, nose, oral, kidney, prostate, bladder, brain, vaginal tract, heart, liver, spleen, tendons, or a wound, or a combination thereof.

### Claim 171 (depends on 167)

The method of claim 167, wherein the subject is immunosuppressed or has an immune cell defect, asplenia, impaired splenic function, nephrotic syndrome, or an autoimmune condition.

### Claim 172 (depends on 157)

A method of producing the composition of claim 157 comprising infecting bacteria with an isolated bacteriophage comprising a bacteriophage sequence that is at least 99% identical to any one of SEQ ID NO:1-74; culturing the bacteria under conditions to allow bacteriophage to replicate; and isolating bacteriophage from the bacteria culture.

### Claim 173 (depends on 157)

A device, comprising, on, in, and/or around the device, the composition of claim 157.
